

Abstract # TPS3185: A First In Human Study of IK-595, an Oral MEK/RAF Molecular Glue, In Patients with RAS- or RAF- Altered Advanced Solid Tumors

Nehal J. Lakhani¹, Alexander I. Spira², Anthony W. Tolcher³, Jason J. Luke⁴, Meredith Mckean⁵, Trupti Lingaraj⁶, Marissa Timothy⁶, Wilmin Bartolini⁶, Nerymar Ortiz-Otero⁶, Katherine Kacena⁶, Caroline Germa⁶, and Sergio Santillana⁶ on behalf of the IK-595 Investigators

¹START Midwest, Grand Rapids, MI, ²NEXT Oncology, Fairfax, VA, ³NEXT Oncology, San Antonio, TX, ⁴UPMC Hillman Cancer Center, Pittsburgh, PA, ⁴Sarah Cannon Research Institute, Nashville, TN, ⁶Ikena Oncology, Boston, MA

Background

- The RAS pathway is implicated in at least half a million new cancer diagnoses each year in the United States
- Current approved MEK inhibitors block MEK kinase activity, however ERK-mediated negative feedback triggers a CRAF bypass mechanism leading to reactivation of the MEK pathway¹
- Additionally, CRAF has kinase-independent activity that promotes tumor growth² that is not inhibited by 1st generation MEK inhibitors
- CRAF plays a critical role in the therapeutic resistance of approved MEK inhibitors in RAS mutant cancer patients¹

First gen MEK inhibitors trigger CRAF mediated

IK-595 traps MEK & RAF in an inactive complex to prevent


Methods

Study Design

- Phase 1, first-in-human, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of IK-595
- IK-595 is an oral drug administered intermittently with the flexibility to explore additional dosing schedules
- Backfilling will be allowed with ≥ 3 patients per dose level once a dose escalation level is deemed safe and sufficient plasma exposures have been achieved

Dose Escalation & Dose Schedule Exploration

Dose Expansion and Combinations Following Dose



IK-595 is a best-in-class MEK/RAF molecular glue that traps MEK in an inactive complex with all RAF isoforms blocking ERK pathway reactivation and broadly impacting the RAS therapeutic space


Rationale

IK-595 was designed to overcome key vulnerabilities of first generation and clinical stage MEK inhibitors³

- ✓ Inhibit MEK mediated ERK1/2 phosphorylation
- ✓ Prevent MEK phosphorylation by RAF
- ✓ Alleviate therapeutic resistance through CRAF mediated bypass and pathway reactivation
- ✓ Block CRAF kinase independent activities
- ✓ Optimized PK profile to target IC90 plasma concentrations widening the therapeutic window

IK-595 may address cancers other MEK inhibitors have been unable to treat³

- ✓ IK-595 has demonstrated robust antitumor activity in preclinical models, including KRAS, NRAS, and non-V600E BRAF mutated tumors as well as RAS-inhibitor resistant models
- ✓ IK-595 could be active in KRAS and NRAS tumors by preventing both feedback activation and by inhibiting the kinase independent function of CRAF




Key Eligibility Criteria

- Advanced and unresectable or metastatic solid tumors with no available therapy known to confer clinical benefit
- Documented RAS/RAF gene alteration determined by local testing
- ECOG performance status of 0 or 1
- Fresh pre-treatment tumor biopsy

Objectives and Endpoints

Primary Objectives/Endpoints

- To determine the safety and tolerability of IK-595
 - Frequency and severity of adverse events
 - Number of patients with dose-limiting toxicities (dose escalation only)
- To determine the RP2D and/or MTD of IK-595 (dose escalation only)



Secondary Objectives/Endpoints

- To determine the PK of IK-595
- To evaluate the pharmacodynamic effects of IK-595 on pERK in paired tumor biopsies
- To assess preliminary antitumor activity - ORR, TTR, DOR, DCR, and PFS

Key Exploratory Objectives/Endpoints

- Overall survival (OS)
- Target engagement and pharmacodynamic activity of IK-595 in peripheral blood cells by measuring changes in pERK levels
- Evaluate the association of baseline tumor biomarkers (mutations, gene or pathway expression) with clinical response
- Monitor changes in tumor burden and evaluate molecular response in longitudinal blood sample collections

Statistical Considerations

- During dose escalation, a minimum of 3 patients will be enrolled in each dose level per the BOIN design
- Backfilling will be allowed with at least 3 additional patients once a dose has been deemed safe by the Safety Review Committee
- A Simon 2-stage adaptive design will be used in dose expansion

References

1- Lito et al. Cancer Cell 2014

2- Venkatanarayan et al. Cell Reports 2022



Visit clinicaltrials.gov for more on this trial

The study opened in December 2023 and is actively enrolling

Enrollment in the first 2 cohorts was completed with no DLTs and dose escalation continues

3- Haines et al. AACR Meeting 2024 5- Martinex-Garcia *et al.* Clin Cancer Res 2012

4- Infante *et al.* Lancet Oncology 2012

Clinical Trial information: NCT06270082

Download this poster and visit our website Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASCO[®] or the author of this poster.

